## Jens Overgaard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2784868/publications.pdf Version: 2024-02-01

		5896	5829
272	27,368	81	161
papers	citations	h-index	g-index
273	273	273	17616
all docs	docs citations	times ranked	citing authors

IENS OVEDCAADD

#	Article	IF	CITATIONS
1	Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy. New England Journal of Medicine, 1997, 337, 949-955.	27.0	2,408
2	Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet, The, 1999, 353, 1641-1648.	13.7	1,493
3	Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet, The, 2006, 368, 843-854.	13.7	967
4	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology, 2005, 77, 18-24.	0.6	867
5	Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 1996, 41, 31-39.	0.6	795
6	Radiation oncology in the era of precision medicine. Nature Reviews Cancer, 2016, 16, 234-249.	28.4	636
7	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet, The, 2003, 362, 933-940.	13.7	626
8	Hypoxic Radiosensitization: Adored and Ignored. Journal of Clinical Oncology, 2007, 25, 4066-4074.	1.6	564
9	Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet, The, 1995, 345, 540-543.	13.7	551
10	Effect of HPV-Associated p16 <sup>INK4A</sup> Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2009, 27, 1992-1998.	1.6	548
11	A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology, 1998, 46, 135-146.	0.6	523
12	Imaging hypoxia to improve radiotherapy outcome. Nature Reviews Clinical Oncology, 2012, 9, 674-687.	27.6	519
13	Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 2008, 26, 1419-1426.	1.6	515
14	The current and potential role of hyperthermia in radiotherapy. International Journal of Radiation Oncology Biology Physics, 1989, 16, 535-549.	0.8	475
15	Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis. Radiotherapy and Oncology, 2011, 100, 22-32.	0.6	404
16	ls the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiotherapy and Oncology, 2007, 82, 247-253.	0.6	402
17	Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Seminars in Radiation Oncology, 1996, 6, 10-21.	2.2	390
18	Hyperthermia: a Potent Enhancer of Radiotherapy. Clinical Oncology, 2007, 19, 418-426.	1.4	389

#	Article	IF	CITATIONS
19	DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. Journal of Clinical Oncology, 2016, 34, 314-320.	1.6	356
20	Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet, The, 1999, 354, 1425-1430.	13.7	329
21	Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. International Journal of Radiation Oncology Biology Physics, 1980, 6, 1507-1517.	0.8	328
22	Study of Failure Pattern Among High-Risk Breast Cancer Patients With or Without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-Term Results From the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies. Journal of Clinical Oncology, 2006, 24, 2268-2275.	1.6	309
23	A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology, 2000, 57, 39-43.	0.6	274
24	Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid: A randomized multicenter study. Cancer, 1986, 58, 22-28.	4.1	268
25	FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiotherapy and Oncology, 2012, 105, 14-20.	0.6	266
26	Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncology, The, 2005, 6, 757-764.	10.7	264
27	Radiotherapy-Related Lung Fibrosis Enhanced by Tamoxifen. Journal of the National Cancer Institute, 1996, 88, 918-922.	6.3	257
28	The impact of hypoxia and its modification of the outcome of radiotherapy. Journal of Radiation Research, 2016, 57, i90-i98.	1.6	229
29	Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer. Cancer Research, 2011, 71, 5923-5931.	0.9	226
30	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncology, The, 2017, 18, 1221-1237.	10.7	226
31	Primary radiotherapy of larynx and pharynx carcinoma—An analysis of some factors influencing local control and survival. International Journal of Radiation Oncology Biology Physics, 1986, 12, 515-521.	0.8	223
32	Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. International Journal of Radiation Oncology Biology Physics, 1989, 16, 1065-1068.	0.8	212
33	Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. International Journal of Hyperthermia, 1996, 12, 3-20.	2.5	201
34	Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiotherapy and Oncology, 2012, 102, 122-129.	0.6	196
35	Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneity. Acta Oncológica, 1994, 33, 383-389.	1.8	177
36	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiotherapy and Oncology, 2010, 94, 30-35.	0.6	177

#	Article	IF	CITATIONS
37	The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiotherapy and Oncology, 2011, 100, 49-55.	0.6	176
38	Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiotherapy and Oncology, 2014, 111, 366-373.	0.6	164
39	Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients. Radiotherapy and Oncology, 2015, 114, 56-65.	0.6	161
40	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology, 2021, 156, 281-293.	0.6	157
41	Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Journal of Clinical Oncology, 2020, 38, 3615-3625.	1.6	155
42	Sensitization of Hypoxic Tumour Cells—Clinical Experience. International Journal of Radiation Biology, 1989, 56, 801-811.	1.8	150
43	Second primary cancers after adjuvant radiotherapy in early breast cancer patients: A national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiotherapy and Oncology, 2013, 106, 42-49.	0.6	148
44	The Influence of Hypoxia and Acidity on the Hyperthermic Response of Malignant Cells <i>In Vitro</i> . Radiology, 1977, 123, 511-514.	7.3	145
45	Cancer of the Nasal Cavity and Paranasal Sinuses: <i>A Clinico-pathological Study of 277 Patients</i> . Acta Oncológica, 1997, 36, 45-50.	1.8	145
46	Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiotherapy and Oncology, 2014, 113, 310-316.	0.6	144
47	Prospective study of 18FDGâ€PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCAâ€13 study. Head and Neck, 2008, 30, 471-478.	2.0	143
48	Hyperthermia: The Optimal Treatment to Overcome Radiation Resistant Hypoxia. Cancers, 2019, 11, 60.	3.7	142
49	Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncológica, 2004, 43, 396-403.	1.8	135
50	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.6	130
51	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â`') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	7.0	127
52	Late Treatment-Related Morbidity in Breast Cancer Patients Randomized to Postmastectomy Radiotherapy and Systemic Treatment Versus Systemic Treatment Alone. Acta Oncológica, 2000, 39, 355-372.	1.8	126
53	TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiotherapy and Oncology, 2005, 75, 18-21.	0.6	125
54	Loco-regional recurrence after mastectomy in high-risk breast cancer—risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiotherapy and Oncology, 2006, 79, 147-155.	0.6	124

#	Article	IF	CITATIONS
55	Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study. BMC Cancer, 2014, 14, 636.	2.6	123
56	Genetic Predictors of Adverse Radiotherapy Effects: The Gene-PARE project. International Journal of Radiation Oncology Biology Physics, 2006, 65, 646-655.	0.8	120
57	Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiotherapy and Oncology, 2018, 126, 107-115.	0.6	116
58	Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiotherapy and Oncology, 2003, 67, 339-344.	0.6	114
59	Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. British Journal of Cancer, 2014, 110, 2072-2080.	6.4	110
60	Early and late radiotherapeutic morbidity in 442 consecutive patients with locally advanced carcinoma of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 1994, 29, 941-952.	0.8	109
61	Clinical correlations between late normal tissue endpoints after radiotherapy: Implications for predictive assays of radiosensitivity. European Journal of Cancer, 1993, 29, 1373-1376.	2.8	104
62	Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2294-2303.	6.4	104
63	Aerobic glycolysis in cancers: Implications for the usability of oxygenâ€responsive genes and fluorodeoxyglucoseâ€PET as markers of tissue hypoxia. International Journal of Cancer, 2008, 122, 2726-2734.	5.1	104
64	Genetic Markers for Prediction of Normal Tissue Toxicity After Radiotherapy. Seminars in Radiation Oncology, 2008, 18, 126-135.	2.2	103
65	Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncology, The, 2010, 11, 553-560.	10.7	103
66	Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma – A prospective study. Radiotherapy and Oncology, 2012, 103, 38-44.	0.6	103
67	The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 2006, 80, 123-131.	0.6	98
68	High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c. Radiotherapy and Oncology, 2009, 90, 74-79.	0.6	98
69	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.6	98
70	Hyperthermia as an adjuvant to radiotherapy in the treatment of malignant melanoma. International Journal of Hyperthermia, 1987, 3, 483-501.	2.5	97
71	Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis. British Journal of Cancer, 1992, 65, 102-107.	6.4	97
72	Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. British Journal of Cancer, 1998, 77, 932-940.	6.4	97

#	Article	IF	CITATIONS
73	Pharyngo-cutaneous fistulae after laryngectomy.Influence of previous radiotherapy and prophylactic metronidazole. Cancer, 1988, 61, 673-678.	4.1	96
74	Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiotherapy and Oncology, 2013, 108, 500-505.	0.6	95
75	Evaluation of comorbidity in 9388 head and neck cancer patients: A national cohort study from the DAHANCA database. Radiotherapy and Oncology, 2014, 110, 91-97.	0.6	94
76	Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Research, 1990, 50, 7430-6.	0.9	93
77	Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522,739 patients. Radiotherapy and Oncology, 2016, 121, 402-413.	0.6	90
78	ldentifying pH independent hypoxia induced genes in human squamous cell carcinomas <i>in vitro</i> . Acta OncolA³gica, 2010, 49, 895-905.	1.8	88
79	Cosmetic Outcome and Breast Morbidity in Breast-Conserving Treatment. Acta Oncológica, 2002, 41, 369-380.	1.8	85
80	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Research, 2017, 19, 44.	5.0	85
81	Glottic carcinoma – patterns of failure and salvage treatment after curative radiotherapy in 861 consecutive patients. Radiotherapy and Oncology, 2002, 63, 257-267.	0.6	84
82	Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment … now!. International Journal of Radiation Oncology Biology Physics, 1995, 32, 1531-1534.	0.8	83
83	Hypopharyngeal Squamous Cell Carcinoma: Treatment Results in 138 Consecutively Admitted Patients. Acta Oncolųgica, 2000, 39, 529-536.	1.8	83
84	The impact of comorbidity on outcome in 12 623 Danish Head and Neck Cancer Patients: A population based study from the DAHANCA database. Acta Oncológica, 2013, 52, 285-293.	1.8	83
85	Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncológica, 2015, 54, 1001-1007.	1.8	82
86	Shoulder disability and late symptoms following surgery for early breast cancer. Acta Oncológica, 2008, 47, 569-575.	1.8	81
87	Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort. Clinical Cancer Research, 2014, 20, 5272-5280.	7.0	80
88	Imaging Hypoxia in Xenografted and Murine Tumors With 18F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, Po2-Polarography, and Fluorescence Microscopy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1202-1212.	0.8	79
89	Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiotherapy and Oncology, 2012, 103, 69-75.	0.6	78
90	TP53Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-negative and Node-positive Breast Cancer. Acta Oncológica, 2000, 39, 327-333.	1.8	76

#	Article	IF	CITATIONS
91	CT-planned internal mammary node radiotherapy in the DBCG-IMN study: Benefit versus potentially harmful effects. Acta Oncológica, 2014, 53, 1027-1034.	1.8	73
92	Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer, 2001, 91, 1500-1509.	4.1	72
93	Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c Acta Oncológica, 2008, 47, 591-599.	1.8	71
94	Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience, 2014, 1, 367-374.	2.2	71
95	Hot Topic: Can mild hyperthermia improve tumour oxygenation?. International Journal of Hyperthermia, 1997, 13, 141-147.	2.5	68
96	Relative biological effectiveness (RBE) and distal edge effects of proton radiation on early damage <i>in vivo</i> . Acta Oncológica, 2017, 56, 1387-1391.	1.8	64
97	Diagnostic intervals before and after implementation of cancer patient pathways – a GP survey and registry based comparison of three cohorts of cancer patients. BMC Cancer, 2015, 15, 308.	2.6	63
98	Resolution in PET hypoxia imaging: Voxel size matters. Acta OncolÃ <sup>3</sup> gica, 2008, 47, 1201-1210.	1.8	62
99	Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002. European Journal of Cancer, 2013, 49, 1627-1633.	2.8	62
100	A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. British Journal of Cancer, 1982, 46, 904-911.	6.4	61
101	Postmastectomy Irradiation in High-Risk Breast Cancer Patients: Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncológica, 1988, 27, 707-714.	1.8	58
102	Long-term colorectal function after postoperative radiotherapy for colorectal cancer. Lancet, The, 1997, 350, 564.	13.7	58
103	Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue. British Journal of Cancer, 1980, 41, 10-21.	6.4	56
104	The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy – Results from the randomized DAHANCA 5 study. Radiotherapy and Oncology, 2011, 98, 28-33.	0.6	56
105	The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. Radiotherapy and Oncology, 2015, 117, 91-98.	0.6	56
106	Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncológica, 2016, 55, 1091-1098.	1.8	55
107	Arrhenius Analysis of Survival Curves from Thermotolerant and Step-Down Heated L1A2 Cells in Vitro. Radiation Research, 1982, 91, 468.	1.5	52
108	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer, 1997, 80, 917-928.	4.1	52

#	Article	IF	CITATIONS
109	Long-term follow-up of late morbidity, cosmetic outcome and body image after breast conserving therapy. A study from the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncológica, 2013, 52, 259-269.	1.8	51
110	Socioeconomic position and stage at diagnosis of head and neck cancer – a nationwide study from DAHANCA. Acta Oncológica, 2015, 54, 759-766.	1.8	51
111	Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? $\hat{a} \in \mathbb{C}^{*}$ Results from the randomized DAHANCA 5 and 7 trials. Acta Oncol $\tilde{A}^{3}$ gica, 2011, 50, 1006-1014.	1.8	49
112	The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. Radiotherapy and Oncology, 2020, 151, 149-151.	0.6	49
113	The heat is (still) on – The past and future of hyperthermic radiation oncology. Radiotherapy and Oncology, 2013, 109, 185-187.	0.6	47
114	Factors associated with acute and late dysphagia in the DAHANCA 6 & amp; 7 randomized trial with accelerated radiotherapy for head and neck cancer. Acta Oncológica, 2013, 52, 1535-1542.	1.8	47
115	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncology, The, 2021, 22, 727-736.	10.7	45
116	The Danish Head and Neck Cancer database. Clinical Epidemiology, 2016, Volume 8, 491-496.	3.0	43
117	Local recurrences after curative IMRT for HNSCC: Effect of different GTV to high-dose CTV margins. Radiotherapy and Oncology, 2018, 126, 48-55.	0.6	41
118	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. Radiotherapy and Oncology, 2020, 149, 189-196.	0.6	41
119	Squamous Cell Carcinoma of the Oropharynx-An Analysis of Treatment Results in 289 Consecutive Patients. Acta Oncológica, 2000, 39, 985-994.	1.8	40
120	Supraglottic carcinoma: patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. International Journal of Radiation Oncology Biology Physics, 2002, 53, 948-958.	0.8	40
121	Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. Seminars in Nuclear Medicine, 2020, 50, 562-583.	4.6	40
122	Identification of accurate reference genes for RT-qPCR analysis of formalin-fixed paraffin-embedded tissue from primary Non-Small Cell Lung Cancers and brain and lymph node metastases. Lung Cancer, 2013, 81, 180-186.	2.0	38
123	IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2015, 116, 15-20.	0.6	38
124	Failure pattern and salvage treatment after radical treatment of head and neck cancer. Acta Oncológica, 2016, 55, 625-632.	1.8	38
125	Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model. Acta Oncológica, 2015, 54, 1623-1630.	1.8	37
126	Effect of hyperthermia on the hypoxic fraction in an experimental mammary carcinoma <i>in vivo</i> . British Journal of Radiology, 1981, 54, 245-249.	2.2	36

#	Article	IF	CITATIONS
127	Factors of importance for the development of the step-down heating effect in a C3H mammary carcinomain vivo. International Journal of Hyperthermia, 1987, 3, 79-91.	2.5	36
128	Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent – A population based study from the DAHANCA group. Radiotherapy and Oncology, 2016, 118, 257-266.	0.6	36
129	Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish Breast Cancer Cooperative Group trial: The DBCG-IMN study. Acta Oncológica, 2013, 52, 1526-1534.	1.8	35
130	Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. Apmis, 1998, 106, 463-469.	2.0	34
131	Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. Acta OncolÃ <sup>3</sup> gica, 2014, 53, 1337-1346.	1.8	34
132	Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study. Journal of Clinical Oncology, 2022, 40, 4198-4206.	1.6	34
133	Effect of carboxyhemoglobin on tumor oxygen unloading capacity in patients with squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology Biology Physics, 1992, 22, 407-410.	0.8	33
134	Image-guided adaptive radiotherapy – integration of biology and technology to improve clinical outcome. Acta Oncológica, 2008, 47, 1182-1185.	1.8	32
135	The value of routine follow-up after treatment for head and neck cancer. A National Survey from DAHANCA. Acta Oncológica, 2013, 52, 277-284.	1.8	32
136	Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncológica, 2014, 53, 654-661.	1.8	32
137	DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiotherapy and Oncology, 2018, 127, 12-19.	0.6	32
138	The Influence of Repeat Surgery and Residual Disease on Recurrence After Breast-Conserving Surgery: A Danish Breast Cancer Cooperative Group Study. Annals of Surgical Oncology, 2015, 22, 476-485.	1.5	31
139	Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays, 2000, 25, 313-9.	0.2	30
140	Importance of margin width in breastâ€conserving treatment of early breast cancer. Journal of Surgical Oncology, 2016, 113, 609-615.	1.7	29
141	APD-Containing Cyclolipodepsipeptides Target Mitochondrial Function in Hypoxic Cancer Cells. Cell Chemical Biology, 2018, 25, 1337-1349.e12.	5.2	27
142	Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts. Acta Oncológica, 2019, 58, 1489-1494.	1.8	27
143	The 5p12 breast cancer susceptibility locus affects <i>MRPS30</i> expression in estrogenâ€receptor positive tumors. Molecular Oncology, 2014, 8, 273-284.	4.6	26
144	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. Radiotherapy and Oncology, 2015, 116, 346-351.	0.6	26

#	Article	IF	CITATIONS
145	Tumour Oxygenation Assessed by Polarographic Needle Electrodes and Bioenergetic Status Measured by <sup>31</sup> P Magnetic Resonance Spectroscopy in Human Soft Tissue Tumours. Acta Oncológica, 1997, 36, 565-571.	1.8	25
146	Audit of the radiotherapy in the DBCG 82 b&c trials—A validation study of the 1538 patients randomised to postmastectomy radiotherapy. Radiotherapy and Oncology, 2005, 76, 285-292.	0.6	25
147	Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression. Radiotherapy and Oncology, 2012, 105, 269-270.	0.6	25
148	Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods. Acta Oncológica, 2017, 56, 1554-1561.	1.8	25
149	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. Radiotherapy and Oncology, 2019, 135, 43-50.	0.6	25
150	PET imaging of tumor hypoxia using <sup>18</sup> F-labeled pimonidazole. Acta Oncológica, 2013, 52, 1300-1307.	1.8	24
151	External validation of a normal tissue complication probability model for radiation-induced hypothyroidism in an independent cohort. Acta Oncológica, 2015, 54, 1301-1309.	1.8	24
152	NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy. Acta Oncológica, 2019, 58, 1410-1415.	1.8	24
153	Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance. Radiotherapy and Oncology, 2019, 130, 75-81.	0.6	24
154	Biology-guided adaptive radiotherapy (BiGART) – more than a vision?. Acta Oncológica, 2013, 52, 1243-1247.	1.8	23
155	Quality assurance of radiation therapy for head and neck cancer patients treated in DAHANCA 10 randomized trial. Acta OncolÃ <sup>3</sup> gica, 2015, 54, 1669-1673.	1.8	23
156	Some problems related to the clinical use of thermal isoeffect doses. International Journal of Hyperthermia, 1987, 3, 329-336.	2.5	22
157	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials. Acta Oncológica, 2018, 57, 38-43.	1.8	22
158	What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. Molecular Oncology, 2020, 14, 1577-1585.	4.6	22
159	A longitudinal study of follow-up activities after curative treatment for head and neck cancer. Acta Oncol³gica, 2015, 54, 813-819.	1.8	21
160	An evaluation of multiplex bead-based analysis of cytokines and soluble proteins in archived lithium heparin plasma, EDTA plasma and serum samples. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 601-611.	1.2	21
161	A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta OncolA <sup>3</sup> gica, 2019, 58, 1495-1501.	1.8	21
162	The emerging evidence for Stereotactic Body Radiotherapy. Acta Oncológica, 2006, 45, 771-774.	1.8	20

#	Article	IF	CITATIONS
163	Completeness and validity in a national clinical thyroid cancer database: DATHYRCA. Cancer Epidemiology, 2014, 38, 633-637.	1.9	20
164	Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. Acta Oncológica, 2017, 56, 59-67.	1.8	20
165	Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial. Radiotherapy and Oncology, 2022, 170, 4-13.	0.6	20
166	Simultaneous Hypoxia and Low Extracellular pH Suppress Overall Metabolic Rate and Protein Synthesis In Vitro. PLoS ONE, 2015, 10, e0134955.	2.5	19
167	Squamous Cell Carcinoma of the Nasopharynx&An Analysis of Treatment Results in 149 Consecuti v e Patients. Acta Oncológica, 2001, 40, 801-809.	1.8	18
168	Chalkley Estimates of Angiogenesis in Early Breast Cancer - Relevance to Prognosis. Acta Oncológica, 2002, 41, 695-703.	1.8	18
169	Advancing radiation oncology through scientific publication – 100 volumes of Radiotherapy and Oncology, 2011, 100, 1-6.	0.6	18
170	Auditory brain stem responses in patients after radiation therapy for nasopharyngeal carcinoma. Cancer, 1992, 70, 2396-2401.	4.1	17
171	Influence of sampling time on assessment of potential doubling time. Cytometry, 1994, 16, 144-151.	1.8	17
172	Biology-guided adaptive radiation therapy – presence or future?. Acta Oncológica, 2010, 49, 884-887.	1.8	17
173	Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Supportive Care in Cancer, 2017, 25, 2179-2185.	2.2	17
174	Differential gene expression in primary fibroblasts induced by proton and cobalt-60 beam irradiation. Acta OncolA³gica, 2017, 56, 1406-1412.	1.8	17
175	Is DBCG abreast of new developments?. Acta Oncológica, 2018, 57, 1-2.	1.8	17
176	Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013. JAMA Network Open, 2020, 3, e2022126.	5.9	17
177	DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity. Radiotherapy and Oncology, 2020, 148, 65-72.	0.6	17
178	Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients. Radiotherapy and Oncology, 2016, 120, 98-106.	0.6	16
179	Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiotherapy and Oncology, 2017, 123, 424-430.	0.6	16
180	Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224). Radiotherapy and Oncology, 2020, 151, 126-133.	0.6	16

#	Article	IF	CITATIONS
181	Long-term follow-up on shoulder and arm morbidity in patients treated for early breast cancer. Acta Oncológica, 2020, 59, 851-858.	1.8	16
182	The Effect of Shark Cartilage Extracts on the Growth and Metastatic Spread of the SCCVII Carcinoma. Acta Oncológica, 1998, 37, 441-445.	1.8	15
183	Collagen fragment biomarkers as serological biomarkers of lean body mass - a biomarker pilot study from the DAHANCA25B cohort and matched controls. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 335-342.	7.3	15
184	Gazing at the crystal ball of European radiotherapy. Nature Reviews Clinical Oncology, 2015, 12, 5-6.	27.6	15
185	Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort. Acta Oncológica, 2016, 55, 983-992.	1.8	14
186	Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncológica, 2018, 57, 3-12.	1.8	14
187	Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models. Anticancer Research, 2014, 34, 6297-304.	1.1	14
188	Pattern of relapse after breast conserving therapy, a study of 1519 early breast cancer patients treated in the Central Region of Denmark 2000–2009. Acta Oncológica, 2016, 55, 964-969.	1.8	13
189	Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. Radiotherapy and Oncology, 2022, 166, 137-144.	0.6	13
190	Radiotherapy and Oncology comes of age. Radiotherapy and Oncology, 2005, 75, 1-5.	0.6	12
191	What next?. Radiotherapy and Oncology, 2014, 110, 1-2.	0.6	12
192	Incidence of and survival after glottic squamous cell carcinoma in Denmark from 1971 to 2011—A report from the Danish Head and Neck Cancer Group. European Journal of Cancer, 2016, 59, 46-56.	2.8	12
193	Does age affect prognosis in salivary gland carcinoma patients? A national Danish study. Acta OncolÅ <sup>3</sup> gica, 2016, 55, 19-22.	1.8	12
194	IMRT – Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncology, 2018, 86, 91-99.	1.5	12
195	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer, 2022, 126, 1082-1090.	6.4	12
196	Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020, 126, 5263-5273.	4.1	11
197	Study of the Population Pharmacokinetic Characteristics of Nimorazole in Head and Neck Cancer Patients Treated in the DAHANCA-5 Trial. Clinical Oncology, 2015, 27, 168-175.	1.4	10
198	Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. Acta Oncolųgica, 2015, 54, 1245-1250.	1.8	10

#	Article	IF	CITATIONS
199	A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma. British Journal of Cancer, 2016, 115, 1096-1104.	6.4	10
200	Danish retinoblastoma patients 1943–2013 – genetic testing and clinical implications. Acta Oncológica, 2016, 55, 412-417.	1.8	10
201	Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. Acta Oncológica, 2020, 59, 666-672.	1.8	10
202	Early Mortality after Radical Radiotherapy in Head and Neck Cancer – A Nationwide Analysis from the Danish Head and Neck Cancer Group (DAHANCA) Database. Clinical Oncology, 2021, 33, 57-63.	1.4	10
203	Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication. Anticancer Research, 2016, 36, 749-56.	1.1	10
204	Validation of a gene expression profile predictive of the risk of radiation-induced fibrosis in women treated with breast conserving therapy. Acta Oncológica, 2015, 54, 1665-1668.	1.8	9
205	Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer. Acta Oncológica, 2018, 57, 102-106.	1.8	9
206	DAHANCA 9 – a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). Acta Oncológica, 2019, 58, 1502-1505.	1.8	9
207	DAHANCA 33: functional image-guided dose-escalated radiotherapy to patients with hypoxic squamous cell carcinoma of the head and neck (NCT02976051). Acta OncolA3gica, 2020, 59, 208-211.	1.8	9
208	Comparison of one-stage direct-to-implant with acellular dermal matrix and two-stage immediate implant-based breast reconstruction—a cohort study. Gland Surgery, 2021, 10, 207-218.	1.1	9
209	Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA. Acta OncolÃ <sup>3</sup> gica, 2022, 61, 127-133.	1.8	9
210	Radiation oncology in the new virtual and digital era. Radiotherapy and Oncology, 2021, 154, A1-A4.	0.6	8
211	Sinonasal cancer in Denmark 2008–2015: a population-based phase-4 cohort study from DAHANCA. Acta Oncológica, 2021, 60, 333-342.	1.8	8
212	Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort. Acta Oncológica, 2022, 61, 153-162.	1.8	8
213	Treatment outcomes and survival following definitive (chemo)radiotherapy in <scp>HPV</scp> â€positive oropharynx cancer: Largeâ€scale comparison of <scp>DAHANCA</scp> vs <scp>PMH</scp> cohorts. International Journal of Cancer, 2022, 150, 1329-1340.	5.1	8
214	Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial. Acta Oncológica, 2018, 57, 1159-1164.	1.8	7
215	Personalised radiation therapy taking both the tumour and patient into consideration. Radiotherapy and Oncology, 2022, 166, A1-A5.	0.6	7
216	Histopathological and morphometric analyses of late rectal injury after irradiation. Apmis, 2000, 108, 216-222.	2.0	6

#	Article	IF	CITATIONS
217	OC-009: Update of the randomised phase III trial DAHANCA 19: Primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck. Radiotherapy and Oncology, 2015, 114, 10.	0.6	6
218	Predictors of continuous tobacco smoking in a clinical cohort study of Danish laryngeal cancer patients smoking before treated with radiotherapy. Acta Oncológica, 2015, 54, 685-692.	1.8	6
219	Radiation-induced morbidity evaluated by high-frequency ultrasound. Acta Oncológica, 2016, 55, 1498-1500.	1.8	6
220	The relative biological effectiveness of antiprotons. Radiotherapy and Oncology, 2016, 121, 453-458.	0.6	6
221	FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach. Acta Oncológica, 2017, 56, 706-712.	1.8	6
222	Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients. Clinical and Translational Radiation Oncology, 2017, 2, 46-52.	1.7	6
223	Rethink radiotherapy – BIGART 2017. Acta Oncológica, 2017, 56, 1341-1352.	1.8	6
224	Breast cancer radiation therapy. Lancet, The, 2020, 396, 1558.	13.7	6
225	Prognostic value of aÂ15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 552-560.	2.0	6
226	Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix. Acta Oncológica, 2022, 61, 172-178.	1.8	6
227	Improving radiotherapy of squamous cell carcinoma of the head and neck (HNSCC) through a continuous process of biological based clinical trials âr' a 40-year experience from the Danish Head and Neck Cancer Group âr' DAHANCA. European Journal of Cancer, 2017, 72, S102.	2.8	5
228	Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. Acta Oncológica, 2017, 56, 1514-1521.	1.8	5
229	Distinguishing recurrence and new primary tumor as well as the origin of neck metastases in head and neck cancer clinical trials by targeted DNA sequencing. Acta OncolA³gica, 2019, 58, 1506-1508.	1.8	5
230	Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes. Acta Oncológica, 2019, 58, 1476-1482.	1.8	5
231	Patterns in detection of recurrence among patients treated for breast cancer. Breast Cancer Research and Treatment, 2020, 184, 365-373.	2.5	5
232	Radiotherapy & Oncology during the COVID-19 pandemic. Radiotherapy and Oncology, 2020, 146, 221-222.	0.6	5
233	Four decades with ESTRO. Radiotherapy and Oncology, 2020, 142, 1-5.	0.6	5
234	Investigating the potential of deep learning for patient-specific quality assurance of salivary gland contours using EORTC-1219-DAHANCA-29 clinical trial data. Acta Oncológica, 2021, 60, 575-581.	1.8	5

#	Article	IF	CITATIONS
235	Deep Heating Using a Movable Applicator Phased Array Hyperthermia System: A preclinical feasibility study. Acta OncolĂ <sup>3</sup> gica, 1994, 33, 451-455.	1.8	4
236	Characterization and Radiosensitivity of Fibroblasts Derived from Squamous Cell Carcinomas of the Head and Neck, and the Surrounding Oral Mucosa. Acta Oncológica, 1998, 37, 697-700.	1.8	4
237	Bridging the valley of death: The new Radiotherapy & Oncology section "First in man – Translational innovations in radiation oncologyâ€: Radiotherapy and Oncology, 2016, 118, 217-219.	0.6	4
238	Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database. British Journal of Cancer, 2021, 125, 458-464.	6.4	4
239	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer, 1997, 80, 917-928.	4.1	4
240	Reinforcement of the abdominal wall with acellular dermal matrix or synthetic mesh after breast reconstruction with the pedicled transverse rectus abdominis musculocutaneous flap. A prospective double-blind randomized study. Journal of Plastic Surgery and Hand Surgery, 2021, 55, 202-209.	0.8	4
241	What is the most effective treatment for head and neck squamous cell carcinoma? An individual patient data network meta-analysis from the MACH-NC and MARCH collaborative groups. European Journal of Cancer, 2017, 72, S101-S102.	2.8	3
242	The management and survival outcomes of nasopharyngeal cancer in the Nordic countries. Acta Oncológica, 2018, 57, 557-560.	1.8	3
243	OC-0271: 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. Radiotherapy and Oncology, 2018, 127, S137-S138.	0.6	3
244	OC-041 DAHANCA 28a: Phase I/II study of acc. hyperfractionated RT, cisplatin and nimorazole in P16-LAHNSCC. Radiotherapy and Oncology, 2019, 132, 21-22.	0.6	3
245	Oncoplastic breast surgery versus conventional breast conserving surgery – a prospective follow-up study of subjective loco-regional late morbidity. Acta Oncológica, 2021, 60, 750-759.	1.8	3
246	Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. Acta Oncológica, 2021, 60, 1472-1480.	1.8	3
247	Impact of tobacco smoking on radiotherapy outcomes in 1875 HPV-positive oropharynx cancer patients Journal of Clinical Oncology, 2019, 37, 6047-6047.	1.6	3
248	Target coverage and local recurrences after radiotherapy for sinonasal cancer in Denmark 2008–2015. A DAHANCA study. Acta Oncológica, 2022, 61, 120-126.	1.8	3
249	Arrhenius analysis of survival curves from thermotolerant and step-down heated L1A2 cells in vitro. Radiation Research, 1982, 91, 468-82.	1.5	3
250	Introduction: Towards Predicting Outcome of Radiotherapy—At Last. Seminars in Radiation Oncology, 2012, 22, 87-90.	2.2	2
251	Second cancers after radiotherapy for early breast cancer. Radiotherapy and Oncology, 2015, 115, 432-433.	0.6	2
252	So long, Farewell, Au revoir, Auf Weidersehen. Radiotherapy and Oncology, 2016, 121, 345-347.	0.6	2

#	Article	IF	CITATIONS
253	OC-0268: FAZA PET hypoxia as a marker of loco-regional recurrence in HNSCC? Results from the DAHANCA 24 trial. Radiotherapy and Oncology, 2018, 127, S136.	0.6	2
254	Subglottic squamous cell carcinoma in Denmark 1971–2015 – a national population-based cohort study from DAHANCA, the Danish Head and Neck Cancer group. Acta Oncológica, 2019, 58, 1509-1513.	1.8	2
255	Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC). Radiotherapy and Oncology, 2019, 130, 191-192.	0.6	2
256	Does the combination of hyperthermia with low LET (linear energy transfer) radiation induce anti-tumor effects equivalent to those seen with high LET radiation alone?. International Journal of Hyperthermia, 2021, 38, 105-110.	2.5	2
257	Independent external validation using the EORTC HNCC-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis. Radiotherapy and Oncology, 2021, 161, 35-39.	0.6	2
258	Living with heritable retinoblastoma and the perceived role of regular follow-up at a retinoblastoma survivorship clinic: †That is exactly what I have been missing'. BMJ Open Ophthalmology, 2021, 6, e000760.	1.6	2
259	Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole. Acta Oncológica, 2015, 54, 1673-1677.	1.8	1
260	Reply to E. Avisar, H. Kuerer, L. Livi et al, and E. Hindié et al. Journal of Clinical Oncology, 2016, 34, 2674-2675.	1.6	1
261	Intrinsic subtype characterization of local recurrences and new contralateral primary tumors in patients with low risk breast cancer. Influence of age and primary surgery. Acta Oncológica, 2017, 56, 1644-1647.	1.8	1
262	In Regards to Stokes et al and Bledsoe etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 804-805.	0.8	1
263	RE: Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal of the National Cancer Institute, 2018, 110, 430-431.	6.3	1
264	Publishing your trial protocols with Acta Oncologica; your contribution to scientific transparency. Acta Oncológica, 2019, 58, 821-821.	1.8	1
265	BICART 2019 – adapting to the future. Acta Oncológica, 2019, 58, 1323-1327.	1.8	1
266	Correlation and prognostic impact of human papilloma virus and p16-expression in advanced hypopharynx and larynx cancer treated with definitive radiotherapy. Acta Oncológica, 2021, 60, 646-648.	1.8	1
267	In vitro hypoxia responsiveness of [18F] FDG and [18F] FAZA retention: influence of shaking versus stagnant conditions, glass versus polystyrene substrata and cell number down-scaling. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 14.	3.9	1
268	<i>No time to die</i> – BiGART is back. The 20th Acta Oncologica Symposium – BIGART 2021. Acta Oncológica, 2022, 61, 117-119.	1.8	1
269	Hypoxia and local tumour control in squamous cell carcinoma of the anus – a hypothesis-generating study. Acta Oncológica, 2022, 61, 1132-1135.	1.8	1
270	Use of tetrahydraindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect <i>in vivo</i> of combined cisplatin, heat and radiation treatment. International Journal of Hyperthermia, 1993, 9, 821-830.	2.5	0

#	Article	IF	CITATIONS
271	Reproductive death of cancer cells induced by femtosecond laser pulses. , 2007, , .		0
272	Patterns in detection of recurrence among patients treated for breast cancer Journal of Clinical Oncology, 2020, 38, e14020-e14020.	1.6	0